Molina Healthcare
MOH
$198.95
+0.43%
Molina Healthcare, Inc. is a managed care organization that provides government-sponsored health insurance through Medicaid, Medicare Advantage, and the individual Marketplace exchanges, managing health benefit risk for more than 5 million members, with over 85% of enrollment tied to state Medicaid contracts concentrated in California, New York, Texas, and Washington. Molina occupies a distinct niche as the largest pure-play government-program insurer, positioning it as a specialist operator rather than a diversified managed care platform competing with UnitedHealth, Centene, and Elevance. The current investor narrative centers on a sharp margin recovery from a deeply loss-making fourth quarter of 2025, when medical cost trends and risk-adjustment pressure drove a $160 million net loss, followed by sequential earnings improvement through 2026 that has restored profitability but left earnings far below prior-year levels. Debate now hinges on whether Medicaid rate updates and the favorable 2027 Medicare Advantage payment increase from CMS can sustainably rebuild margins, or whether elevated medical cost utilization and a shrinking membership base will keep the recovery fragile, a tension reflected in the stock's volatile but ultimately strong 12-month performance.…
MOH
Molina Healthcare
$198.95
Investment Opinion: Should I buy MOH Today?
Rating: Hold. Molina is a margin-recovery turnaround trading at a modest 3.4% discount to the $216.29 average analyst target with a consensus hold rating (mean 2.74), and the core thesis is that sequential earnings improvement from the Q4 2025 trough can continue as Medicaid rates catch up to medical cost trends. The stock is not cheap on forward earnings (21.8x) but is extremely cheap on sales (0.19x PS), so the investment case is entirely about whether margins normalize.
Supporting evidence is mixed but leans constructive on recovery: net income improved from -$160 million in Q4 2025 to $14 million in Q1 2026 and $60 million in Q2 2026; trailing free cash flow is positive at $271 million; the balance sheet holds $5.09 billion of cash with a 1.69 current ratio; and the stock has outperformed SPY by 16.78 points over 12 months. However, revenue is declining 4.84% YoY, gross margin has compressed to 8.97% from 10.21%, and Q2 operating cash flow was -$294 million, so the recovery is early and unproven. The 0.19x PS and 8.73x EV/EBITDA are consistent with a low-multiple government-program insurer rather than a premium platform, and with no industry-average multiples provided, the clearest benchmark is Molina's own history, where PS has fallen from 2.3x-2.5x in 2022 to 0.19x today.
The biggest risks that could invalidate the thesis are a renewed medical cost shock (as in Q4 2025), continued membership attrition from Medicaid redeterminations, and failure to reach the $23.86 consensus EPS that the 21.8x forward multiple already discounts. This Hold would upgrade to Buy if gross margin recovers above 10% and operating cash flow turns sustainably positive, or if the stock pulls back toward the $180-$190 support zone while the earnings trajectory holds. It would downgrade to Sell if gross margin falls below 8.5%, revenue declines accelerate beyond 5%, or a large state Medicaid contract is lost. On balance, the stock is fairly valued to modestly undervalued relative to its own history but not yet proven cheap relative to the earnings recovery it requires.
Sign up to view all
MOH 12-Month Price Forecast
Molina is a margin-recovery story at an inflection point, with earnings improving sequentially but still far below prior-year levels and revenue shrinking. The 0.19x PS ratio prices in deep skepticism, while the 21.8x forward PE prices in a full earnings recovery — a contradiction that will resolve based on quarterly medical cost ratio results. The CMS 2027 Medicare Advantage rate increase and a liquid $5.09 billion cash balance provide support, but negative Q2 operating cash flow of -$294 million and a 4.81 short ratio keep volatility elevated. I would upgrade to bullish if gross margin recovers above 10% with positive operating cash flow, and downgrade to bearish if gross margin falls below 8.5% or a major state contract is lost.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Molina Healthcare's 12-month outlook, with a consensus price target around $219.53 and implied upside of +10.3% versus the current price.
Average Target
$219.53
0 analysts
Implied Upside
+10.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$163 - $266
Analyst target range
Seventeen analysts cover Molina with a consensus recommendation of "hold" and a mean rating of 2.74 on a scale where 1 is strong buy and 5 is strong sell, indicating a neutral-to-cautious stance. The average target price of $216.29 implies roughly 3.4% upside from the current $209.15, a modest gap that signals the stock is trading close to fair value in the eyes of the Street. The consensus leans neutral rather than bullish, consistent with the recent institutional ratings flow, which shows a wall of Hold/Equal Weight/Sector Perform ratings from Wells Fargo, Truist, RBC, TD Cowen, and JP Morgan, punctuated by Barclays maintaining an Underweight — notably, there have been no upgrades in the visible ratings history, only reiterations. The target range is wide, from $147 to $266, a spread of 81% of the current price that signals genuine disagreement about the earnings trajectory. The high target of $266 (about 27% above the current price) likely assumes successful Medicaid rate updates, medical cost trend moderation, and a return toward the $23.86 consensus EPS estimate, implying multiple expansion on normalized earnings. The low target of $147 (about 30% below current) prices in persistent medical cost pressure, further membership attrition, and margin compression that keeps earnings well below estimates. The wide dispersion, combined with the absence of recent upgrades and the presence of an Underweight rating, suggests conviction is low and the stock's direction will hinge on quarterly medical cost ratio results rather than analyst sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: MOH Investment Factors
The bear case currently has stronger near-term evidence: revenue is shrinking 4.84% YoY, net margin is only 1.04% versus 2.2%-3.3% historically, and Q2 operating cash flow was -$294 million, while the analyst consensus is a hold with just 3.4% upside to the $216.29 average target. The bull case rests on the dramatic sequential earnings recovery ($60 million in Q2 versus a $160 million Q4 loss), a deeply compressed 0.19x PS ratio, and the CMS 2027 Medicare Advantage rate increase that improves forward visibility. The single most important tension is whether Medicaid rate updates and medical cost trend moderation can restore margins toward the $23.86 consensus EPS estimate — if they do, the 21.8x forward PE is cheap; if medical costs stay elevated, that multiple is expensive on earnings that never materialize. Momentum and relative strength favor the bulls, but fundamentals and Street sentiment favor caution, making this a show-me story decided quarter by quarter on the medical cost ratio.
Bullish
- Sharp margin recovery off Q4 trough: Net income rebounded from a $160 million loss in Q4 2025 to $14 million in Q1 2026 and $60 million in Q2 2026, with EPS recovering from -$2.77 to $1.19. This sequential improvement shows the medical cost shock is being contained and the earnings trajectory has inflected.
- Deep valuation discount to history: PS ratio has compressed from 2.3x-2.5x in 2022 to just 0.19x today, near the bottom of its historical band, while EV/Sales is 0.148x and EV/EBITDA 8.73x. A return to even 0.5x PS would imply substantial upside if margins normalize.
- Strong relative momentum vs. market: MOH is up 29.91% over the past year versus SPY's 13.13%, a 16.78-point relative advantage, and has gained 10.45% in the past month against a -1.02% decline in SPY (11.47-point one-month relative strength). The stock is re-accelerating, not fading.
- CMS 2027 MA rate increase tailwind: A larger-than-expected 2027 Medicare Advantage payment increase from CMS boosted sentiment across managed care, improving revenue visibility for Molina's $1.565 billion Medicare segment. This provides a structural tailwind for margin rebuild into 2027.
Bearish
- Revenue contracting 4.84% YoY: Q2 2026 revenue of $10.874 billion fell 4.84% from $11.427 billion a year earlier, extending sequential decline from $11.375 billion in Q4 2025. Until Medicaid redetermination-driven membership attrition stabilizes, the top line is a headwind rather than a contributor to recovery.
- Margins still far below prior levels: Net margin of 1.04% and operating margin of 1.72% compare with 2.2%-3.3% net margins in mid-2024, and gross margin of 8.97% is down from 10.21% in Q2 2025. Medical cost ratio pressure remains the core unresolved issue.
- Negative quarterly operating cash flow: Q2 2026 operating cash flow was -$294 million, driven by a $415 million working capital outflow, and the price-to-cash-flow ratio is -16.48. The earnings recovery is not yet self-funding, which raises questions about quality of earnings.
- Analyst consensus hold, no upgrades: Seventeen analysts rate MOH a hold with a mean of 2.74, and the average target of $216.29 implies only 3.4% upside. The visible ratings history shows only reiterations — including a Barclays Underweight — with no upgrades, signaling low conviction.
MOH Technical Analysis
Molina is in a sustained, if choppy, uptrend, with the stock up 29.91% over the past year versus a 13.13% gain for SPY, a relative strength advantage of 16.78 percentage points. At the current price of $209.15, the stock sits at roughly 71% of its 52-week range of $121.06 to $244.89, positioning it in the upper-middle of the band — close enough to highs to reflect constructive momentum but not so extended as to signal overextension. The 39.66% maximum drawdown over the period underscores that this uptrend has been punctuated by violent reversals rather than a smooth advance. Short-term momentum is clearly positive and accelerating: the stock gained 10.45% over the past month and 5.87% over three months, with the one-month relative strength of 11.47 points against a -1.02% decline in SPY indicating the stock is moving in the opposite direction of a softening market. This one-month surge outpaces the three-month gain, suggesting re-acceleration rather than deceleration, though the most recent session's -3.46% drop from $216.64 to $209.15 is a reminder of the stock's tendency toward sharp single-day reversals. The 4.81 short ratio indicates a meaningful short interest that can amplify both rallies and selloffs. Key resistance sits at the 52-week high of $244.89, roughly 17% above the current price; a breakout above that level would confirm the recovery trend and likely trigger short covering. Support rests at the 52-week low of $121.06, though the more relevant near-term floor is the $180-$190 zone that repeatedly held during September and early October 2026. The debt-to-equity ratio of 0.97 is a balance-sheet metric rather than a volatility gauge, but the stock's 39.66% max drawdown and 4.81 short ratio together imply beta-like volatility well above the market, warranting smaller position sizing and wider stops.
Beta
0.78
0.78x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$121-$245
Price range past year
Annual Return
+24.1%
Cumulative gain past year
| Period | MOH Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | +0.7% |
| 3m | +1.7% | +3.0% |
| 6m | +3.2% | +6.8% |
| 1y | +24.1% | +11.9% |
| ytd | +11.5% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOH Fundamental Analysis
Revenue is contracting, a red flag for a growth-oriented managed care story: second-quarter 2026 revenue of $10.874 billion fell 4.84% year over year from $11.427 billion in Q2 2025, extending a pattern of sequential decline from $11.375 billion in Q4 2025 and $11.147 billion in Q1 2025. Segment data shows Medicaid Solutions generating $8.049 billion and Medicare $1.565 billion, with Marketplace at $628 million and other segments at $26 million — meaning Medicaid, the segment most exposed to state rate actions and redetermination dynamics, drives roughly 74% of revenue and is the primary swing factor. The revenue decline likely reflects membership attrition from Medicaid redeterminations and Marketplace pricing actions, and until enrollment stabilizes, top-line growth cannot contribute to the earnings recovery. Profitability has improved dramatically off a trough but remains thin: Q2 2026 net income of $60 million compares with a $160 million loss in Q4 2025 and $14 million in Q1 2026, yet is down sharply from $255 million in Q2 2025. Net margin of 1.04% and operating margin of 1.72% are characteristic of the low-single-digit margins typical in Medicaid-heavy managed care, but the current level is well below the 2.2%-3.3% net margins Molina posted in mid-2024, indicating substantial room for margin repair. Gross margin of 8.97% versus 10.21% in Q2 2025 confirms medical cost ratio pressure is the core issue. The balance sheet is liquid but cash generation is a concern: the current ratio of 1.69 is solid, and cash stands at $5.09 billion, but trailing free cash flow is only $271 million and Q2 2026 operating cash flow was -$294 million, driven by a $415 million working capital outflow. Debt-to-equity of 0.97 and a negative price-to-cash-flow ratio of -16.48 reflect the cash flow strain, while ROE of 11.6% and ROA of 1.07% are modest; the company is not dependent on external financing given its cash position, but the negative quarterly FCF means the recovery is not yet self-funding.
Quarterly Revenue
$10.9B
2026-06
Revenue YoY Growth
-4.8%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$271000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOH Overvalued?
Because net income is positive ($60 million in Q2 2026), the PE ratio is the appropriate primary metric, and the trailing PE of 19.43x against a forward PE of 21.82x is unusual — the forward multiple exceeds the trailing, implying the market expects earnings to decline from trailing levels, consistent with the fact that trailing EPS of $0.05 reflects a depressed base while forward estimates of $23.86 per share imply a dramatic earnings recovery that the current multiple does not yet capture. The 19.4x trailing PE on near-zero earnings is mechanically distorted, so the more meaningful read is the forward PE of 21.8x against estimated EPS of $23.86, which prices in a full margin normalization. On a price-to-sales basis, the 0.19x PS ratio and 0.148x EV/Sales are extremely low, reflecting the thin-margin, high-revenue nature of the Medicaid business and suggesting the market assigns little value to each revenue dollar. Peer comparison is constrained by the absence of industry-average multiples in the provided valuation data, but the 0.19x PS and 8.73x EV/EBITDA are consistent with a low-multiple government-program insurer rather than a premium managed care platform; the 2.17x price-to-book is moderate. The forward PE of 21.8x versus a PEG ratio of -0.34 (negative due to depressed trailing earnings) makes growth-adjusted valuation uninformative. Historical context is instructive: Molina's PE ranged from roughly 12x-20x in 2023-2024 when earnings were healthy, spiked to 48x in Q2 2026 and 123x in Q1 2026 on collapsed earnings, and its PS ratio has compressed from 2.3x-2.5x in 2022 to 0.19x today — near the bottom of its historical band. That compression reflects both the revenue decline and the margin collapse; a return to even 0.5x PS would imply substantial upside, but the market is pricing in skepticism about the durability of the earnings recovery.
PE
19.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~48x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are concentrated in margin fragility and cash generation. Net margin of 1.04% and operating margin of 1.72% leave almost no buffer, and gross margin has fallen to 8.97% from 10.21% a year ago, meaning a modest uptick in medical cost utilization can wipe out earnings entirely — as it did in Q4 2025 when Molina posted a $160 million net loss. Revenue is contracting 4.84% YoY to $10.874 billion, and with Medicaid at $8.049 billion (roughly 74% of revenue) and over 85% of members in state programs concentrated in California, New York, Texas, and Washington, a single adverse rate action or redetermination wave in one large state can move the entire P&L. Q2 2026 operating cash flow of -$294 million, driven by a $415 million working capital outflow, and a negative price-to-cash-flow ratio of -16.48 show the recovery is not yet self-funding, even though $5.09 billion of cash and a 1.69 current ratio provide near-term liquidity.
Market and competitive risks center on valuation ambiguity and sector dynamics. The 21.8x forward PE exceeds the 19.4x trailing PE, an unusual inversion that implies the market expects earnings to fall from trailing levels even as consensus models $23.86 of forward EPS — a disconnect that leaves the stock vulnerable to any estimate reset. Molina competes against far larger diversified players (UnitedHealth, Centene, Elevance) with more pricing power and diversification, and as a pure-play government insurer it has less ability to offset Medicaid pressure with commercial or pharmacy businesses. The stock's 39.66% maximum drawdown and 4.81 short ratio imply beta-like volatility well above the market, and the recent -3.46% single-session drop from $216.64 to $209.15 shows how quickly sentiment can reverse. The CMS 2027 Medicare Advantage rate increase is a positive, but it is already reflected in sector sentiment and does not address the Medicaid cost trend that drives most of Molina's revenue.
In a worst-case scenario, medical cost trends stay elevated through 2027, state Medicaid rate updates lag utilization, membership attrition continues, and the $23.86 consensus EPS proves unreachable. The stock would likely retest its 52-week low of $121.06, roughly 42% below the current $209.15, and could approach the analyst low target of $147 (about 30% below current) if estimates are cut but not abandoned. A more moderate adverse path to the $147 low target implies a loss of roughly 30%, while a full retest of the 52-week low implies a loss of about 42%. Given the 39.66% max drawdown already experienced in the past year, this downside is not hypothetical — it is the demonstrated behavior of this stock when the margin thesis breaks.
FAQ
The most severe risk is financial: net margin of 1.04% and gross margin of 8.97% leave almost no buffer, and a medical cost shock like the one that produced the $160 million Q4 2025 loss could recur. Second is revenue concentration and attrition: Medicaid is roughly 74% of revenue ($8.049 billion) with over 85% of members in state programs concentrated in four states, so a single adverse rate action or redetermination wave is highly damaging, and revenue is already declining 4.84% YoY. Third is cash flow quality: Q2 2026 operating cash flow was -$294 million with a $415 million working capital outflow and a -16.48 price-to-cash-flow ratio. Fourth is market/valuation risk: the 39.66% max drawdown, 4.81 short ratio, and 21.8x forward PE leave the stock vulnerable to estimate cuts and sharp reversals such as the recent -3.46% single-session drop.
The 12-month forecast has three scenarios: a 25% bull case targeting $244.89-$266 if Medicaid rates catch up and gross margin recovers above 10%; a 50% base case targeting $209.15-$216.29 if margins repair only gradually and earnings land below the $23.86 consensus; and a 25% bear case targeting $121.06-$147 if medical costs re-accelerate and estimates are cut. The base case is most likely, anchored by the $216.29 average analyst target and the assumption that the medical cost ratio stabilizes without materially improving. The key assumption behind the base case is that revenue decline moderates toward flat as Medicaid redeterminations annualize and operating cash flow turns modestly positive. A breakout above $244.89 or a break below the $180-$190 support zone would shift the probabilities.
The valuation is contradictory depending on the metric. On sales, MOH is extremely cheap at 0.19x PS and 0.148x EV/Sales, far below the 2.3x-2.5x PS it commanded in 2022, suggesting the market assigns little value to each revenue dollar. On earnings, the 21.8x forward PE against $23.86 consensus EPS is not cheap and actually exceeds the 19.4x trailing PE, implying the market expects earnings to decline from trailing levels. The 8.73x EV/EBITDA and 2.17x price-to-book are moderate for a low-margin government-program insurer. The market is pricing skepticism about the durability of the margin recovery — if margins normalize, the stock is undervalued; if they do not, the forward multiple is expensive on earnings that never materialize.
MOH offers a modest 3.4% upside to the $216.29 average analyst target with a consensus hold rating (mean 2.74), so the risk/reward is balanced rather than compelling at the current $209.15. The bull case rests on a sharp sequential earnings recovery — from a $160 million Q4 2025 loss to $60 million in Q2 2026 — and a historically cheap 0.19x PS ratio. The bear case is that revenue is shrinking 4.84% YoY, net margin is only 1.04%, and Q2 operating cash flow was -$294 million, with downside to the $147 analyst low target (about 30%) or the $121.06 52-week low (about 42%). It is a reasonable buy only for risk-tolerant investors who believe Medicaid rate updates will restore margins, and a poor fit for conservative portfolios given the 39.66% max drawdown and 4.81 short ratio.
MOH is better suited to a medium-term holding period of 12-18 months than to either short-term trading or multi-year compounding. The stock is in a margin-recovery phase with earnings visibility limited to quarterly medical cost ratio results, and its 39.66% max drawdown, 4.81 short ratio, and sharp single-day reversals (such as the recent -3.46% drop) make short-term trading risky without tight stops. It pays no dividend (payout ratio 0), so there is no income component to support a long-term hold, and the 21.8x forward PE already discounts much of the recovery. A concrete minimum holding period of 12 months allows time for state Medicaid rate updates and the CMS 2027 Medicare Advantage increase to flow through margins, while monitoring gross margin above 8.97% and operating cash flow turning positive as the key checkpoints.